Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scolr Pharma, a specialty pharmaceutical company, has announced that Daniel Wilds has resigned as CEO of the company and as a member of its board of directors.
Subscribe to our email newsletter
The company will be managed by its existing executive management team on an interim basis.
Michael Taglich, chairman of the board of Scolr Pharma, said: “On behalf of the board of directors and Scolr’s entire organization, I would like to thank Dan for his more than five years of vision and leadership.
“We are focused on advancing our extended release CDT ibuprofen towards an FDA submission in 2009. We believe we are well positioned to achieve advantageous alliances with major pharmaceutical companies and other potential partners.”